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Abstract
Background:  99mTc-HMPAO is a well-established isotope useful in the detection of regional
cerebral blood flow. Diabetes gives rise to arterial atherosclerotic changes that can lead to
significant end organ dysfunction, prominently affecting perfusion to the heart, kidneys, eyes and
brain. In the current study, we investigated the role of 99mTc-HMPAO cerebral perfusion scans in
detecting early vascular changes in the diabetic brain.
Methods: Cerebral perfusion studies were performed on both control and streptozotocin-(STZ)
induced diabetic male Wistar rats. Rat brain imaging using a gamma camera was performed for each
group 0.5, 2, 4, and 24 hours post 99mTc-HMPAO injection. Data processing for each cerebral
perfusion scan was performed by drawing a region of interest (ROI) circumferentially around the
brain (B). Background (BKG) due to signal from the soft tissue of each rat was subtracted. Brain
99mTc-HMPAO uptake minus background counts (net brain counts; NBC) were then compared
between the two groups.
Results: The NBC (mean ± SD) for the STZ group were statistically significantly higher (p =
0.0004) than those of the control group at each of the time points studied.
Conclusion: 99mTc-HMPAO brain scan may be useful in the detection of early atherosclerotic
changes in the diabetic rat brain.
Background
Diabetes leads to early atherosclerotic changes through a
number of mechanisms, including the formation of
advanced glycosylation end products and its influence on
serum lipid composition. The vascular complications of
diabetes are significant, and can lead to a severe arteriop-
athy prominently affecting the heart, kidneys and eyes.
The brain can also be affected, causing impairments in
memory and learning.
Nuclear medicine studies have previously been utilized
for the functional investigation of diabetic pathophysiol-
ogy. For example, in the podiatric literature, nuclear med-
icine imaging has been shown to be helpful in the
management of the diabetic foot [1]. The role of cerebral
nuclear medicine imaging techniques in the detection of
CNS manifestations of diabetes has been studied previ-
ously using 18F fluorodeoxyglucose (18F-FDG) positron
emission tomography (PET), to assess brain glucose
metabolism [2,3] in diabetic patients. Four studies have
examined cerebral perfusion in diabetes using SPECT [4-
7], three in type 1 diabetics and one in type 2 diabetics.
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Technetium 99m-hexamethylpropylene amine oxime
(99mTc-HMPAO) cerebral perfusion scanning is a well-
known nuclear medicine test used to detect variations in
regional brain blood flow. 99mTc-HMPAO is the most
common radiotracer used for SPECT and planar brain
imaging; it is a lipophilic radiotracer that crosses the
blood brain barrier (BBB). 99mTc-HMPAO is thought to
accumulate in the brain through its intracellular conver-
sion from a lipophilic to a hydrophilic form within the
brain parenchyma [8]. Under most conditions, blood
flow is coupled to increases in cerebral metabolism; hence
99mTc-HMPAO images can be used to represent the func-
tional status of the brain.
To our knowledge, no prior studies have investigated the
use of 99mTc-HMPAO uptake in the detection of vascular
signal changes in early diabetic rats. Therefore, in the
present study we investigated the potential role of 99mTc-
HMPAO cerebral perfusion scanning in the detection of
early vascular changes in new-onset diabetes.
Methods
Materials
A HMPAO (Exametazime) kit was purchased from Amer-
sham (UK). 99mTc was eluted from a fresh 99Mo-99mTc gen-
erator (Amersham, UK). All other reagents used in this
study were supplied by Sigma-Aldrich (UK).
Animals
Adult male Wistar rats (n = 12) of ~200 g weight were
raised and handled in accordance with ethical standards,
approved by the institutional ethics committee as recom-
mended by the Helsinki Declaration.
Preparation of 99mTc-HMPAO
Fresh elutes of technetium (99mTc) were used each time to
prepare the 99mTc-HMPAO following the manufacturer's
instructions and recommendations. In brief, 1110–2960
MBq of 99mTcO4 in 5 ml of saline were added to a freeze-
dried Exametazime kit to produce 99mTc-HMPAO.
Induction of experimental type 1 diabetes
Experimental type 1 diabetes was induced in rats by intra-
peritoneal (i.p.) injection of 55 mg/kg streptozotocin
(STZ) dissolved in citrate buffer. Control rats were
injected with buffer only.
Blood glucose determination
Blood samples were collected from the tail vein. Basal glu-
cose levels were determined prior to STZ injection, using
an automated blood glucose analyzer (Glucometer Elite
XL). Sample collections were then made 48 h after STZ
injection and blood glucose concentrations were deter-
mined and compared between groups. Rats with blood
glucose concentrations above 300 mg/dl were declared
diabetic and were used in the experimental group. One
week after the induction of experimental diabetes, imag-
ing was performed.
Experimental protocol
In order to control pain, an intravenous line was placed in
the dorsal tail vein of each rat 10–15 minutes before the
time of the radiopharmaceutical injection. Each rat was
subsequently anaesthetized by intraperitoneal (i.p.) injec-
tion with 0.5 ml of 0.5 g intraval sodium 10 minutes
before  99mTc-HMPAO injection. The level of anesthesia
achieved with this regimen lasted for ~4 hours. Another
i.p. injection of 0.5 g intraval sodium was administered
before imaging at the 24 hour point. This anesthetic agent
is believed to have a negligible effect on both blood pres-
sure and the biodistribution of the radiopharmaceutical.
129.5 MBq of 99mTc-HMPAO was injected within 30 min-
utes of 99mTc-HMPAO preparation and followed by a
saline push administered via the fixed intravenous line.
Each rat underwent a brain scan 30 minutes after 99mTc-
HMPAO injection.
Gamma camera imaging
Each scan was performed using a single-head gamma (γ)
camera (Philips camera; Odyssey LX) equipped with a
high-resolution parallel hole collimator connected to a
Dell computer. The matrix was 128 × 128 pixels and the
photopeak was focused at 140 keV with a symmetric 10%
window. Planar (posterior static view) images were
obtained using a 5 minute acquisition at each time point.
Each anaesthetized rat was fixed with plastic tape on a fix-
ing board against the table of the γ camera during acquisi-
tion. The rat's head was localized in the center of the field
of view and a zoom factor of 4 was applied during each
acquisition time.
Image processing
Data processing for brain scans was done by drawing a
region of interest (ROI) circumferentially around the
brain (B) and around the soft tissues of the neck of each
rat as a background measurement (BKG). Brain 99mTc-
HMPAO uptake minus background (net brain counts;
NBC) in control rats were determined first and expressed
as the mean ± standard deviation (mean ± SD). NBC in
diabetic-STZ rats were then determined. The ROIs were
drawn with a fixed pixel size in order to maintain compa-
rability between groups.
Data presentation and statistical analysis
All data, unless otherwise stated, were expressed as the
mean ± standard deviation (mean ± SD). A Kruskal-Wallis
non-parametric analysis of variance (ANOVA) test was
used to evaluate differences between the STZ diabetic
group and the control group. In addition, differences
between the two groups at each time point were assessed.BMC Medical Physics 2008, 8:1 http://www.biomedcentral.com/1756-6649/8/1
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Statistical analysis was performed using SPSS version 13.0
software (Chicago, USA).
Results
Induction of diabetes by STZ resulted in a significant
increase in blood glucose concentration (mean ± SD),
from 180 ± 6 mg/dl (pre-STZ) to 350 ± 8 mg/dl (post-STZ)
after one week of induction.
The net 99mTc-HMPAO brain counts (NBC) in the control
group (mean ± SD) at 0.5, 2, 4 and 24 h were 67,766 ±
10,405; 49,439 ± 6,960; 37,080 ± 5,459; and 2,017 ± 302
counts per second (cps) respectively. NBC for the STZ
group at 0.5, 2, 4 and 24 h were 241,296 ± 3,548; 148,215
± 2,316; 111,254 ± 1,682; and 6,817 ± 76 cps respectively.
There was a highly significant difference between the con-
trol and STZ groups (p = 0.004) and there was no signifi-
cant difference between each time point at both control
and STZ groups (p = 0.416) using the non-parametric test
equivalent to the analysis of variance (ANOVA), the
Kruskal-Wallis test. Figure 1 shows 99mTc-HMPAO net
brain counts (NBC) for both control and STZ-treated rats.
Discussion
Our results indicate that there are highly significant
changes in the cerebral vasculature that occur early in the
brains of diabetic rats, as demonstrated by an increase in
99mTc-HMPAO NBC. We found evidence of significantly
increased 99mTc-HMPAO brain uptake one week after the
induction of diabetes in the diabetic-STZ group compared
to the control group at all time points from 0.5 h to 24 h.
This may be due to early pathophysiological changes,
such as vasodilatation in the early stages of diabetes asso-
ciated with increased glucose metabolism. In agreement
with our results, several prior studies have reported a sig-
nificant increase in overall basal cerebral blood flow
(CBF) rates in STZ-induced diabetic rats [9-11] as well as
in diabetic patients using 99mTc-HMPAO SPECT [4,5]. In
contrast, one clinical study reported a 25–30% decrease in
CBF in type 2 diabetic patients compared to control sub-
jects [7]. These apparent inconsistencies may actually
reflect time-dependent differences in the pathophysio-
logic course of diabetes; however, more definitive longitu-
dinal studies are needed to evaluate this hypothesis.
Typically, blood flow parallels the rate of glucose metabo-
lism in the cerebrum. The increased 99mTc-HMPAO brain
uptake observed in this study may be related to increased
demand for, and/or accumulation of glucose uptake one
week after the induction of diabetes.
99mTc-HMPAO uptake was reported to accumulate signif-
icantly and to relate to an enhanced rate of glucose metab-
olism in malignant cancer cells such as in human breast
tumor cell lines (MCF-7) in vitro [12]. This illustrates one
manner in which CBF and glucose metabolism may be
related. However, not all studies are consistent: in a group
of patients with newly diagnosed type 1 diabetes, no
changes in cerebral glucose metabolism were detected
[13]. Furthermore, a group of patients with long-standing
diabetes exhibited a 15–20% reduction in cerebral glu-
cose metabolism, again possibly reflecting a time-depend-
ent process [13]. Another potential confounding factor is
the comparison of studies performed with different imag-
ing modalities and radiopharmaceuticals, as the latter
study was performed using [18F]-2-deoxy-2-fluoro-D-glu-
cose (18F-FDG) PET [13].
Conclusion
99mTc-HMPAO brain scan may be useful in the early diag-
nosis of cerebral vasculopathic changes in early diabetic
rats. Future studies should be performed to confirm our
findings and to further delineate the relationship between
diabetes and CBF characterized by 99mTc-HMPAO.
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